PRESS RELEASE FROM 8K10Q.COM · November 20, 2026

Sent by 8K10Q.com, the research site Mr. Nejmeh founded. It names this case. As sent, word for word:

8K10Q.com - We read. It's never as it seems.

PRESS RELEASE · 8K10Q.com SPECIAL REPORT

When Your Lover Tells You “I Love You, I Just Slept with Your Best Friend”: How a Stock Analyst Rolls

Payola for Your Pills: How Stock Analysts Get Paid

November 20, 2026 – In small biotech, a handful of analysts publish the research individual investors read before they buy. A new 8K10Q.com special report asks who pays them, and answers from the companies’ own SEC filings.

8K10Q.com read every final offering prospectus filed by drug and biotech companies from July 15 to November 19, 2026. In those four months, 56 companies raised $6.53 billion from investors in 62 stock sales. The banks that sold the shares were paid $309.4 million in cash fees, as the prospectuses themselves state. Today, 44 of the 57 stocks with a price record trade below where they closed the day before their raise. In two of the raises, China SXT Pharmaceuticals sold warrants that can be turned into up to 135 million shares for no cash at all; the company itself says it expects no cash from them.

The banks that publish research on drug companies are the same banks collecting those fees. FINRA’s own rule bars paying an analyst for a specific deal, but allows his pay to depend on the firm’s investment banking revenue, as long as the research report discloses it (Rule 2241(c)(4)(B)). The 8K10Q.com report puts each bank’s fee in plain view, raise by raise.

One company from the record: when Theriva Biologics was named Pipex, it paid Crystal Research Associates $35,000 while Crystal’s co-founder, Jeffrey Kraws, was a Pipex director and vice president (Form 10-KSB/A, August 29, 2008). Analysts from A.G.P., Maxim Group and H.C. Wainwright, all of them banks that sell biotech shares, have covered Theriva. Theriva is the defendant in Nejmeh v. Theriva Biologics, Inc., 3:26-cv-00705 (D. Nev.); in its November 12, 2026 quarterly report, Theriva says the lawsuit made it “aware of the fact that the definitive proxy statement for the 2026 Annual Meeting contained errors.” Theriva’s own filings can be read in plain English on 8K10Q.com.

“It’s like your lover telling you, ‘I love you. I slept with your best friend,’” said Mark Nejmeh, founder of 8K10Q.com. “The analyst says buy, and the same filing shows his firm got paid to sell you the shares. Every investor should know this game, for every stock on the market.”

“Based on my calculations, the wealth gap comes partly from stock losses caused by facts hidden in the filings,” Nejmeh said. “Companies that used warrants alone lost their investors $16.54 trillion. Everyone better wake up, because as AI repositions your job, investing has to become part of your income.”

The $16.54 trillion is WarrantWire.com’s count from every annual report filed with the SEC from 2001 to 2026: what 7,696 companies that used warrants were worth at the start, plus the money they raised, minus what is left today. Its sister site, 8K10Q.com, reads the filings behind any of those companies.

The full report, bank by bank, is free at 8k10q.com/payola. 8K10Q.com reads any SEC filing in plain English and puts a card on every officer, auditor, lawyer and analyst. WarrantWire.com tracks the warrants behind the deals: $16.54 trillion in market value lost by 7,696 companies that used warrants.

About Mark Nejmeh

Mark Nejmeh is an inventor and early internet builder who wrote an AI public-bidding program in 1984 and launched one of the first online auctions. He founded 8K10Q.com and WarrantWire.com to read SEC filings for individual investors, and he is the plaintiff in Nejmeh v. Theriva Biologics (3:26-cv-00705, D. Nev.).

Contact: [email protected] · 215-219-7699 · 8K10Q.com

Sources: the companies’ final offering prospectuses (Form 424B), July 15 – November 19, 2026, each read in full; Theriva Biologics Form 10-KSB/A (Aug 29, 2008) and Form 10-Q (Nov 12, 2026); FINRA Rule 2241; daily closing prices, Yahoo Finance, November 18, 2026.

8K10Q.com · WarrantWire.com · We read. It’s never as it seems.

Mr. Nejmeh owns Theriva shares. While the case is pending he will not buy or sell any Theriva shares, warrants or options (statement of October 27, 2026). Allegations in the pending case are allegations; no court has ruled on them.